Sexually transmitted infections are a massive health challenge with more than a million new infections occurring every day. Increased investment in research and development for new vaccines is key to halting the spread of genital herpes, gonorrhoea, chlamydia, syphilis, and trichomoniasis, according to a new special issue of the journal Vaccine, co-edited by WHO and the United States’ National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH).
Antimicrobial resistance in gonorrhoea
The rapidly changing antimicrobial
susceptibility of Neisseria gonorrhoeae has
created an important public health problem.
The Gonococcal Antimicrobial Surveillance Programme (GASP) has documented the emergence and spread of antimicrobial resistance in gonorrhoea since 1992 and has provided evidence to inform national, regional, and global treatment guidelines.
Investing in screening and treatment for syphilis in pregnant women ranks as one of the most cost-effective antenatal interventions. Screening all pregnant women, using simple and low-cost technologies, is feasible, even in low-resource settings. Syphilis is easily cured with penicillin, and MTCT of syphilis is easily prevented when pregnant mothers with syphilis infection are identified early and treated promptly.
STIs are a major global cause of acute illness, infertility, long-term disability and death, with serious medical and psychological consequences to millions of men, women and infants. Efforts to control STIs require strong surveillance systems. Effective surveillance is crucial to monitoring epidemic trends, identifying severe or emerging epidemic outbreaks, strategically directing resources for prevention, treatment, and control efforts, and assessing the effectiveness of these efforts.